The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Does bridging therapy affect lymphoma CAR-T outcomes?
Whether bridging therapy affects the outcomes of patients with lymphoma who receive CAR-T is unknown. Here, Michael Jain, MD, PhD, Moffitt Cancer Center, Tampa, FL, explains the characteristics and outcomes of large B-cell lymphoma patients receiving bridging therapy while awaiting axicabtagene ciloleucel therapy from the US Lymphoma CAR T Consortium analysis. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
